Walleye Trading’s abrdn Life Sciences Investors HQL Stock Holding History

Walleye Trading’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-14,200	Closed	-$213K	–	4389
2020 Q1	$213K	Buy	14,200 +1,600	+13%	+$26.2K	﹤0.01%	2561
2019 Q4	$220K	Buy	+12,600	New	+$207K	﹤0.01%	3089

Other funds holding HQL

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Matisse Capital Portland, Oregon $234M AUM 19.72% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

Cohen & Steers New York $57.6B AUM 8.03% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

1CP

1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return

Walleye Trading's HQL Position: Q2 2020 in Review

Walleye Trading sold out of abrdn Life Sciences Investors (HQL) in Q2 2020, closing a stake of 14,200 shares — an estimated $213K sold.

Walleye Trading first reported a position in HQL in Q4 2019 and held it in 2 quarters. The position peaked at $220K in Q4 2019. 70 funds tracked by Wall St. Rank hold HQL as of Q2 2020.

Walleye Trading reported no remaining abrdn Life Sciences Investors position as of Q2 2020 after selling out during the quarter.
Walleye Trading sold 14,200 abrdn Life Sciences Investors shares in Q2 2020, an estimated $213K.
Walleye Trading first reported a position in abrdn Life Sciences Investors in Q4 2019 and held it in 2 quarters.
Walleye Trading's abrdn Life Sciences Investors position peaked at $220K in Q4 2019.
70 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2020.

Based on Walleye Trading's 13F filing for Q2 2020, filed 14 Aug 2020.